Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 17/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | IDH1 | O75874 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21216848 | 0.88 | NR1H4 (0.44) | NR1H4 | |
| SCHEMBL22772582 | 0.87 | NR1H4 (0.50) | NR1H4 | |
| SCHEMBL2003480 | 0.86 | NR1H4 (0.45) | NR1H4 | |
| SCHEMBL2002892 | 0.86 | NR1H4 (0.54) | NR1H4TP53MAPT | |
| SCHEMBL19900665 | 0.84 | MAPT (0.60) | NR1H4TP53MAPT | |
| SCHEMBL30437437 | 0.84 | MAPT (0.60) | NR1H4TP53MAPT | |
| SCHEMBL1999960 | 0.82 | NR1H4 (0.42) | NR1H4 | |
| SCHEMBL2003228 | 0.82 | NR1H4 (0.50) | NR1H4TP53MAPT | |
| SCHEMBL2004785 | 0.82 | NR1H4 (0.50) | NR1H4TP53MAPT | |
| SCHEMBL19899890 | 0.82 | MAPT (0.49) | NR1H4TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4691553-A2 | FXR (NR1H4) MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4534536-A1 | FXR (NR1H4) MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2025-04-09 | — | — | EP | disclosed |
| US-20250026744-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2025-01-23 | — | — | US | disclosed |
| CN-113302190-B | FXR (NR 1H 4) modulating compounds | 吉利德科学公司 | 2024-10-18 | — | — | CN | disclosed |
| EP-4089072-B1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2024-08-28 | — | — | EP | disclosed |
| EP-4360632-A2 | FXR (NR1H4) MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| CN-117924266-A | Compounds that modulate FXR (NR 1H 4) | 吉利德科学公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-117924267-A | Compounds that modulate FXR (NR 1H 4) | 吉利德科学公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-109476636-B | Compounds that modulate FXR (NR 1H 4) | 吉利德科学公司 | 2024-01-09 | — | — | CN | disclosed |
| EP-3911647-B1 | ISOXAZOLE COMPOUND AS FXR AGONIST AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | GILEAD SCIENCES INC (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20200071282-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2020-03-05 | — | — | US | disclosed |
| US-20190308962-A1 | FXR (NR1H4) Modulating Compounds | GILEAD SCIENCES, INC. (US) | 2019-10-10 | — | — | US | disclosed |
| US-10421730-B2 | FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2019-09-24 | — | — | US | disclosed |
| US-10421730-B2 | FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2019-09-24 | — | — | US | disclosed |
| EP-3257847-B1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2019-08-21 | — | — | EP | disclosed |
| WO-2017218330-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2017-12-21 | — | — | WO | disclosed |
| EP-3257847-A1 | FXR (NR1H4) MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2017-12-20 | — | — | EP | disclosed |
| US-20170355685-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355685-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355685-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190308962-A1 | FXR (NR1H4) Modulating Compounds | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885TP53 4347/4885MAPT 3650/4885 |
| US-20250026744-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885TP53 3801/4885MAPT 3674/4885 |
| US-10421730-B2 | FXR (NR1H4) modulating compounds | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885TP53 4165/4885MAPT 3594/4885 |
| US-20170355685-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885TP53 4165/4885MAPT 3594/4885 |
| US-20200071282-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885TP53 4165/4885MAPT 3594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.